CRISPR Therapeutics AG (CRSP)
49.98
-2.80 (-5.30%)
USD |
NASDAQ |
Jan 30, 16:00
49.98
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 3.914B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -10.18% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 305.65 |
| Price to Book Value | 2.003 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 81.34% |
News
Headline
Wire
Time (ET)
MT Newswires
01/19 08:43
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/15/2023* | -- | Results | Q4 2022 | -- | -2.27 | -- | |
| 11/01/2022 | -- | Results | Q3 2022 | -2.24 | -2.24 | -0.09% | |
| 08/08/2022 | -- | Results | Q2 2022 | -2.40 | -2.21 | -8.83% | |
| 05/09/2022 | -- | Results | Q1 2022 | -2.32 | -1.97 | -17.61% | |
| 02/15/2022 | -- | Results | Q4 2021 | -1.84 | -1.78 | -3.35% | |
| 11/03/2021 | -- | Results | Q3 2021 | -1.67 | -1.76 | 5.29% | |
| 07/29/2021 | -- | Results | Q2 2021 | 9.44 | 3.12 | 202.6% | |
| 04/27/2021 | -- | Results | Q1 2021 | -1.51 | -1.47 | -2.59% |
*Estimated Date/Time
Earnings
Profile
Edit
| CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes. |
| URL | http://www.crisprtx.com |
| Investor Relations URL | http://ir.crisprtx.com/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Value |
| Next Earnings Release | Feb. 15, 2023 (est.) |
| Last Earnings Release | Nov. 01, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of January 27, 2023.
Fundamentals
| Revenue (TTM) | 12.78M |
| Total Expenses (TTM) | 700.10M |
| Net Income (TTM) | -680.85M |
| Total Assets (Quarterly) | 2.353B |
| Total Liabilities (Quarterly) | 399.40M |
| Shareholders Equity (Quarterly) | 1.954B |
| Cash from Operations (TTM) | -468.45M |
| Cash from Investing (TTM) | -91.84M |
| Cash from Financing (TTM) | 42.41M |
Ratings
Profile
Edit
| CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes. |
| URL | http://www.crisprtx.com |
| Investor Relations URL | http://ir.crisprtx.com/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Value |
| Next Earnings Release | Feb. 15, 2023 (est.) |
| Last Earnings Release | Nov. 01, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| GLQ | 6.466M USD | 4.39% |
| GLO | 11.80M USD | 4.38% |
| ADNRX | 10.15M USD | 4.27% |
| ARKK | 287.33M USD | 3.71% |
| ARKG | 83.28M USD | 3.65% |
| GNOM | 8.290M USD | 3.58% |
| IDNA | 5.265M USD | 3.14% |
| F000010GK0 | 14.30M USD | 2.72% |
| FCOVGX | 237583.0 USD | 2.38% |
| KRXCX | 392100.0 USD | 2.31% |
| LSCGX | 1.973M USD | 2.07% |
| CLOVX | 667397.0 USD | 1.90% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| CRSP Tweets |